Second Alzheimer's slowing drug to seek approval in the US
Donanemab has proven to slow disease progression by several months in some patients but has also shown serious side effects. Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening by about four to seven months, researchers reported on Monday. Eli Lilly and Co. is…
#elilillyandco #leqembi #lilly #johnsims #amsterdam